

Piramal Enterprises (India): Demerger of Piramal Pharma Changes in FTSE RAFI™ Index Series

25 August 2022

Subject to the completion of the demerger of Piramal Pharma (India) from Piramal Enterprises (India, constituent), please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
FTSE RAFI All World 3000 Index	30 August 2022
FTSE RAFI All World 3000 Index - QSR	30 August 2022
FTSE RAFI Emerging Index	30 August 2022
FTSE RAFI Emerging Index - QSR	30 August 2022

Please note:

1. The listing date of Piramal Pharma have not yet announced therefore it will remain in the index at a static estimated price until its trading commences on the exchange. If the trading day remains unknown after 20 business days, FTSE Russell will review the company in accordance with the FTSE Russell Spin-offs policy.
2. A capital repayment which is equivalent to the entitlement value of Piramal Pharma will be applied to Piramal Enterprises on the ex-entitlement date.
3. The number of shares of Piramal Pharma is based on the demerged terms of 4 Piramal Pharma shares per every 1 Piramal Enterprises share held.
4. ICB Classification of Piramal Pharma will be 20103015 (Pharmaceuticals).

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 6441 1440
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2022 FTSE Russell